News

Welcome to Episode 2 of the Simply CMT Podcast! Join us as we talk with Jonah Berger, CMTA National Youth Programs Manager and Director of Camp Footprint. Jonah shares his journey living with CMTX, the impact of CMTA’s Youth and ...

Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies for rare diseases, recently announced a successful financing that will allow them to address CMT through its innovative therapeutic candidate, ALE2. According to the company, ALE2 targets mutations in tRNA ...

Charcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy, affecting millions of people worldwide. Despite its prevalence, many people are unfamiliar with CMT and its impact. That’s why CMTA created a new video to explain what CMT is and raise ...

What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, a France-based biotech company, is seeking participants for an online survey to understand patient perspectives on a new genetic therapy under development for CMT1A. According to the company, the therapy offers ...

NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD670, the investigational drug the company is studying in its ongoing Phase II SYNAPSE-CMT clinical trial. ...